1. Academic Validation
  2. Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors

Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors

  • Bioorg Med Chem Lett. 2018 Jul 1;28(12):2195-2200. doi: 10.1016/j.bmcl.2018.05.003.
Siem Jakob Veenstra 1 Heinrich Rueeger 1 Markus Voegtle 1 Rainer Lueoend 1 Philipp Holzer 1 Konstanze Hurth 1 Marina Tintelnot-Blomley 1 Mathias Frederiksen 1 Jean-Michel Rondeau 2 Laura Jacobson 3 Matthias Staufenbiel 3 Ulf Neumann 3 Rainer Machauer 4
Affiliations

Affiliations

  • 1 Department of Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
  • 2 Center for Proteomic Chemistry, Structural Biology Platform, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
  • 3 Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
  • 4 Department of Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland. Electronic address: rainer.machauer@novartis.com.
Abstract

New amino-1,4-oxazine derived BACE-1 inhibitors were explored and various synthetic routes developed. The binding mode of the inhibitors was elucidated by co-crystallization of 4 with BACE-1 and X-ray analysis. Subsequent optimization led to inhibitors with low double digit nanomolar activity in a biochemical and single digit nanomolar potency in a cellular assays. To assess the inhibitors for their permeation properties and potential to cross the blood-brain-barrier a MDR1-MDCK cell model was successfully applied. Compound 8a confirmed the in vitro results by dose-dependently reducing Aβ levels in mice in an acute treatment regimen.

Keywords

Alzheimer’s disease; Amino-1,4-oxazines; BACE-1; P-gp; pK(a).

Figures
Products